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Objective: This study was undertaken to compare mitral valve repair and replace-
ment as treatments for ischemic mitral regurgitation.
Methods: From 1985 through 1997, a total of 482 patients with ischemic mitral
regurgitation underwent either valve repair (n = 397) or valve replacement (n = 85).
Patients more likely (P ≤ .01) to undergo repair had functional mitral regurgitation
or coronary revascularization with an internal thoracic artery graft; those more
likely to receive valve replacement were in higher New York Heart Association
functional classes or underwent emergency operations. These factors were used for
multivariable propensity matching. Risk factors for early and late death were iden-
tified by multivariable, multiphase hazard function analysis.
Results: Within the propensity-matched better-risk group, survivals after valve replace-
ment were 81%, 56%, and 36% at 30 days, 1 year, and 5 years, but survivals after repair
were 94%, 82%, and 58% at these intervals (P = .08). In contrast, within the poor-risk
group, survivals after repair and replacement were similar (P = .4). Risk factors (P ≤
.01) included older age, higher functional class, greater wall motion abnormality, and
renal dysfunction. Approximately 70% of patients were predicted to benefit from
repair; the benefit lessened or was negated if an internal thoracic artery graft was not
used, if a lateral wall motion abnormality was present, or if the mitral regurgitation jet
pattern was complex. Freedom from repair failure at 5 years was 91%.
Conclusion: Late survival is poor after surgery for ischemic mitral regurgitation. Most
patients with ischemic mitral regurgitation benefit from mitral valve repair. In the
most complex, high-risk settings, survivals after repair and replacement are similar.
Surgical treatment of ischemic mitral regurgitation is associated with ahigh operative mortality rate and poor long-term survival. Choosingthe most appropriate surgical treatment to maximize survival forthese patients is made difficult by inconsistent classification schemesfor the entity, a paucity of long-term data to compare alternatives,and an absence of randomized trials of valve repair versus valve
replacement. In fact, such trials are unlikely ever to be undertaken. The purposes
of this study were therefore to develop a simple and clinically useful echocardio-
graphic classification scheme, to determine which patients were more likely to
receive valve repair rather than replacement at this center, to determine whether
survival was better after mitral valve repair or replacement, to discover which
patients benefit from valve repair and which from replacement, and to quantify the
durability of valve repair.
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Methods
Patients
Study group. From 1985 through 1997, records of 482 consec-
utive patients undergoing either mitral valve repair (n = 397) or
replacement (n = 85) for ischemic mitral regurgitation were found.
The Cardiovascular Information Registry was used to discriminate
nearly 2000 potential patients with this condition. Their clinical
records were reviewed to determine whether their mitral regurgita-
tion was indeed caused by ischemic heart disease and did not just
coexist with it (see Definitions section). All patients had at least 2+
(moderate) mitral regurgitation. The decision to perform mitral
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valve surgery was made by the operating surgeon and the cardiol-
ogist on the basis of clinical presentation and findings at cardiac
catheterization and echocardiography. In general it has been our
policy to perform mitral valve surgery for mitral regurgitation that
is 3+ or greater. Patients with any degree of mitral regurgitation
who did not undergo a surgical procedure on the mitral valve were
not included in this study. Patients who underwent concomitant
aortic valve procedures were also excluded and are discussed in a
separate report. Patients who underwent left ventricular restoration
procedures (Batista procedure, Dor procedure) were also excluded
and similarly are discussed in separate reports.
TABLE 1. Patient characteristics
Total Mitral repair Mitral replacement
(n = 482) (n = 397) (n = 85)
No. % No. % No. % P
Demographic characteristics
Age (y) .4*
<50 26 5 23 6 3 4
≥50-60 83 17 72 18 11 13
≥60-70 187 39 149 38 38 45
≥70 186 39 153 39 33 39
Male 261 54 221 56 40 47 .15
Cardiac comorbidity
NYHA functional class† <.0001*
I 1 0.2 1 0.2 0 0
II 155 32 143 37 12 14
III 143 30 121 31 22 26
IV 175 36 124 32 51 60
Emergency surgery 37 8 12 3 25 29 <.0001
Preoperative intra-aortic balloon pump 58 12 30 8 28 33 <.0001
Left main coronary artery disease (≥50%) 100 21 88 22 12 14 .1
Left anterior descending coronary 406 84 348 88 58 68 <.0001
artery disease (≥50%)
Lateral circumflex coronary 384 80 312 79 72 85 .2
artery disease (≥50%)
Right coronary artery disease (≥50%) 427 89 359 90 68 80 .006
Coronary system disease (≥50%) .002
0 3 0.6 2 0.5 1 1
1 49 10 36 9 13 15
2 122 25 94 24 28 33
3 308 64 265 67 43 50
Myocardial infarction‡
Within 14 d of surgery 95 20 62 16 33 39 <.0001
>14 d before surgery 382 80 332 84 50 60 <.0001
Left ventricular dysfunction .0003§
None 56 12 37 9 19 22
Mild 77 16 61 15 16 19
Moderate 180 32 150 38 30 35
Severe 169 35 149 38 20 24
*Logistic test for trend.
†Could not be determined for 8 patients undergoing mitral valve repair.
‡Timing of myocardial infarction could not be determined for 5 patients.
§Logistic test for trend.
Data unavailable for 47 repair group and 11 replacement group patients.
¶Data missing for 6 repair group and 26 replacement group patients.
**Missing values for 73 repair group and 11 replacement group patients.
††Logistic test for trend.
‡‡Missing values for 11 repair group and 2 replacement group patients.
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The mean age of patients undergoing mitral valve repair was 67
± 9.2 years, similar to that among those receiving mitral valve
replacement (67 ± 8.7 years, P = .4). Patient characteristics overall
and according to whether the patient underwent repair or mitral
valve replacement are tabulated in Table 1.
Definitions. Ischemic mitral valve disease was classified from
analysis of clinical information, operative reports, and echocardio-
grams. Mitral regurgitation was judged to be ischemic in origin
when the valve leaflets and chordae were normal and the regurgi-
tation was caused by the consequences of a myocardial infarction.
Thus all patients in this study had at least one previous myocardial
infarction. Twenty percent of these events were within 2 weeks of
surgery. Ten patients with transient mitral regurgitation caused by
intermittent ischemia were not included in this study, even though
they underwent valve repair. Patients with ischemic heart disease
but also clear evidence of degenerative, rheumatic, or infective
mitral valve disease were also excluded. Patients with isolated rup-
tured chordae were considered to have degenerative mitral valve
disease.
Ischemic mitral regurgitation was further subdivided into
three mechanisms of regurgitation: (1) ruptured papillary muscle,
(2) infarcted papillary muscle without rupture, and (3) functional
regurgitation. Patients with elongated and infarcted but unrup-
tured papillary muscles were classified as having infarcted papil-
lary muscles. Patients with isolated functional mitral
regurgitation had normal papillary muscles, chordae, and
leaflets; however, the leaflets failed to coapt, and echocardio-
grams frequently demonstrated restricted leaflet motion. Thus
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patients with functional mitral regurgitation included those with
Carpentier type I and IIIb leaflet motion. Mitral regurgitation was
functional in 76% of the cases, papillary muscle infarction with-
out rupture was present in 24%, and papillary muscle rupture was
present in 9% (Table 2). Components of both papillary muscle
pathologic changes and functional regurgitation were present in
9% of the cases.
Echocardiograms. Echocardiograms for analysis of the regur-
gitant jet direction were available for 364 patients (76%). Jet direc-
tion was recorded as anterior, posterior, central, or complex (Table
2). A complex jet was specified when there were multiple jets or
the jet was eccentric (eg, posterolateral or anterolateral).
Regional wall motion abnormalities were documented with
echocardiograms or ventriculograms from cardiac catheterization
(Figure 1). Abnormalities were categorized as being anterior, sep-
tal, inferior, posterior, and lateral in location (Appendix I, Table 1;
Figure 1).
Surgical details. The 482 operations were performed by 14
surgeons. Of these, 6 performed 32 or more operations, and each
was considered a variable in the analysis. The remaining 8 sur-
geons, who performed 2 to 15 operations each, were grouped for
analysis. The most common repair technique was mitral annulo-
plasty (98%); this was the only repair technique in 314 cases (79%;
Table 3). Eighteen of 42 patients (43%) with papillary muscle rup-
ture underwent mitral valve repair, with papillary muscle reim-
plantation in 12 cases. Among the patients who received mitral
valve replacement, 50 (59%) received bioprostheses and 35 (41%)
received mechanical valves. Concomitant coronary artery bypass
Wall motion abnormality
Anterior 171 40 153 43 18 24 .002
Septal 163 42 146 42 17 23 .003
Posterior 262 63 221 63 41 55 .2
Lateral 186 44 155 44 31 42 .08
Inferior 303 73 257 73 46 67 .05
Atrial fibrillation 159 33 132 33 27 32 .8
Previous cardiac surgery 110 23 95 24 15 18 .2
Noncardiac comorbidity
Hypertension¶ 290 64 238 64 52 66 .8
Chronic obstructive pulmonary disease 93 19 70 18 23 27 .05
Diabetes (treated with oral hypoglycemic 131 27 105 28 26 32 .5
agents or insulin)
Renal dysfunction 43 9 32 8 11 13 .15
Creatinine (mg/dL)** .02††
<1.1 111 28 99 31 12 16
≥1.1-1.3 100 25 78 24 22 30
≥1.3-1.6 99 25 78 24 21 28
≥1.6 88 22 69 21 19 26
Blood urea nitrogen (mg/dL)‡‡ .06**
<17 111 24 97 25 14 17
≥17-23 132 28 111 29 21 25
≥23-29 108 23 89 23 19 23
≥29 118 25 89 23 29 35
TABLE 1. Patient characteristics—Cont’d
Total Mitral repair Mitral replacement
(n = 482) (n = 397) (n = 85)
No. % No. % No. % P
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grafting was performed in 460 cases (95%), 385 (97%) in the
repair group and 75 (88%) in the replacement group (P = .002). An
internal thoracic artery (ITA) graft was used for 17 (20%) of the
patients who received mitral valve replacement and 185 (47%) of
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the patients who underwent repair (P < .0001). Twenty patients
(4%) underwent concomitant tricuspid valve repair.
Follow-up. Patients were followed up systematically at 2-year
intervals with a mailed questionnaire, a telephone interview, or
examination at The Cleveland Clinic Foundation. Follow-up
extended reliably to 7 years, with 1296 patient-years of informa-
tion available for analysis. Mean follow-up among survivors was
3.3 ± 2.4 years, with 50% followed up for more than 2 years, 25%
for more than 4 years, and 10% for more than 6 years.
Data Analysis
Overview. The data analysis first addressed the question, “Were
patients undergoing mitral valve repair similar to those undergoing
replacement?” The answer to that question was no. Therefore a
matched group of patients was assembled to answer a second ques-
tion: “Is survival better after mitral valve repair than after replace-
ment?” However, these patients represented only one end of the
spectrum of ischemic mitral regurgitation (the most complex with
the sickest patients). Multivariable analyses of mortality were
therefore performed separately for repair and replacement groups.
These analyses were then combined, including an analysis of inter-
actions, to yield an overall equation for comparison of repair and
replacement propensity-adjusted for selection factors in choice of
procedure. We then asked, “Which patients benefit from which
procedure?” Multivariable simulation was used to answer that
question. Finally, we asked, “Is mitral valve repair durable?” We
answered this question by analyzing repair failure. Details of the
methodology are supplemented by material in Appendix II.
Were patients undergoing mitral valve repair similar to those
undergoing replacement? To answer this question, multivariable
logistic regression was used to identify factors associated with
TABLE 3. Mitral valve repair techniques (n = 397)
Technique No. %
Annuloplasty 388 98
Annuloplasty type
Carpentier-Edwards 134 34
Cosgrove-Edwards Annulo- 140 35
plasty System*
Bovine pericardial graft 112 28
Autologous pericardium 2 0.5
Annuloplasty size (mm)†
26 80 30
28 73 28
30 58 21
32 43 16
34 10 4
36 4 1
Leaflet resection 17 4
Papillary muscle shortening 34 10
Papillary muscle reimplantation 12 3
Chordal shortening 27 7
Chordal transfer 9 2
*In 1 case an Alfieri stitch was also used.
†Includes only patients with Carpentier-Edwards or Cosgrove-Edwards
annuloplasty (n = 274); data unavailable for 6 patients.
TABLE 2. Valve pathophysiology
Total Mitral repair Mitral replacement
(n = 482) (n = 397) (n = 85)
No. % No. % No. % P
Classification of ischemic mitral regurgitation
Functional 365 76 327 82 38 45 <.0001
Alone* 322 67 294 74 28 33 <.0001
With infarcted papillary muscle 43 9 33 8 10 12 .3
Without rupture 39 8 31 8 8 9
With rupture 4 0.8 2 0.5 2 2
Infarcted papillary muscle 160 33 103 26 57 67 <.0001
Without rupture* 117 24 84 21 33 39 .0006
With rupture* 43 9 19 5 24 28 <.0001
Mitral regurgitation jet direction†
Central 211 58 187 61 24 41 .005
Anterior 24 7 17 6 7 12 .08
Posterior 74 20 56 18 18 31 .03
Complex 55 15 46 15 9 16 .9
Severity of mitral regurgitation
2 23 5 22 6 1 1 <.0001
3 216 45 198 50 18 22
4 236 50 172 44 64 77
*These categories are mutually exclusive.
†Data were unavailable for 91 repair group and 27 replacement group patients.
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valve repair rather than replacement. In this analysis demographic
characteristics, symptoms and clinical status, left ventricular func-
tion, pathyphysiology of valve disease, cardiac comorbidity, non-
cardiac comorbidity, and concomitant coronary artery procedure
variables were considered (Appendix III). Details of risk factor
identification are given in Appendix II. After examining these
patient factors we explored surgeon differences.
The latter parsimonious analysis was amplified into a propen-
sity model by adding nonsignificant variables representing gender,
body size (body mass index), preoperative use of an intra-aortic
balloon pump, coronary system disease greater than 50%, hyper-
tension, treated diabetes, peripheral vascular disease, chronic
obstructive pulmonary disease, history of smoking, concomitant
coronary artery bypass grafting, and all indicator variables for
missing values.1-3 The concordance obtained with this model was
represented by a C statistic of 0.92.
The patients were then sorted according to their individual
propensity score and for some analyses were divided into five
quintiles of equal numbers of patients for comparison of repair ver-
sus replacement among closed propensity-matched patients.
Is survival better after mitral valve repair than after replace-
ment? To answer this question, initial nonparametric estimates of
survival were obtained by the Kaplan-Meier method. A parametric
method was used to resolve the number of phases of instantaneous
risk of death (hazard function) and to estimate its shaping parame-
ters.4 Exploratory analyses of the variables in Appendix III
included correlation analysis, stratified life table analyses, and
decile risk analysis of ordinal and continuous variables to deter-
mine possible transformations of scale needed to calibrate prop-
erly the variables to survival. Thereafter multivariable analysis was
performed in the hazard function domain. In all analyses we forced
the variable mitral valve repair versus mitral valve replacement
and the propensity score. Details of the methods for managing
missing values for variables and for the strategies of variable selec-
tion are given in Appendix II.
Which patients benefit from which procedure? The overall
multivariable survival equation was solved twice for each patient,
once as though the patient’s mitral valve had been replaced and
once again as though a repair had been performed (simulation).
The difference between predicted 7-year survivals for these two
strategies was compared. A positive difference was interpreted as
a repair benefit, and a negative difference was interpreted as a
replacement benefit. The comparison included multiple linear
regression of the 7-year survival differences. Details of this analy-
sis are given in Appendix II.
Analysis of echocardiographic features. Lateral wall motion
abnormality and complex regurgitant jet direction were both risk
factors. Their correlates were explored with multivariable logistic
regression by the techniques described previously.
Is mitral valve repair durable? Durability of mitral valve repair
was assessed by the time-related event mitral valve replacement for
recurrent mitral regurgitation. We considered a repair failure to
have occurred when the repair was completed and then assessed,
generally by removal of cardiopulmonary bypass, with the finding
of important residual mitral valve regurgitation. If this failure
resulted in mitral valve replacement, it was called a repair failure;
these few cases were carried in the mitral valve repair group
throughout the analyses according to the strategy of intent to treat.
Presentation. Mortality and survival estimates are accompa-
nied by an asymmetric 68% confidence interval, comparable to
±1 SE.
Figure 1. Sites of left ventricular wall motion abnormalities in
patients with ischemic mitral regurgitation. Schematic represen-
tation of short-axis view of left ventricle corresponding to labeled
figure below. Papillary muscles are denoted by circles.
Figure 2. Survival after mitral valve surgery for all patients with
ischemic mitral regurgitation. Each symbol represents a death
according to Kaplan-Meier estimator. Vertical bars enclose asym-
metric 68% confidence limits. Solid lines represent parametric
survival estimates; these are enclosed between dashed 68% con-
fidence limits. Numbers in parentheses are numbers of patients
traced beyond that point.
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Results
Were Patients Undergoing Mitral Valve Repair Similar
to Those Undergoing Replacement?
The characteristics of patients undergoing valve repair and
valve replacement differed (Tables 1 and 2). Factors associ-
ated with a greater likelihood of mitral valve repair versus
replacement included nonemergency surgery, isolated func-
tional mitral regurgitation, and use of ITA grafting. Factors
associated with replacement were higher New York Heart
Association (NYHA) functional class and more severe regurgi-
tation (Table 4). When identifiers for surgeons were entered,
two surgeons were found, after adjustment for patient factors,
to be more likely to repair than to replace the valve (P ≤ .01, C
statistic = 0.88), but no factors became statistically significant.
Is Survival Better After Mitral Valve Repair Than
After Replacement?
The answer to the question of survival was not simple but
depended on patient characteristics. Various lines of evi-
dence for this answer are detailed here and are summarized
in Appendix IV.
Overall survival. Fifty-four patients (11%, confidence
interval 9%-13%) died in the hospital. Operative mortality
Surgery for Acquired Cardiovascular Disease Gillinov et al
rate (including those dying within 30 days) was 13% (con-
fidence interval 11%-14%). Time-related survivals were
77% at 1 year and 55% at 5 years (Figure 2).
Propensity-Matched Comparison
Among propensity-matched patients in quintile I, survivals
were similar after mitral valve repair and replacement
(Figure 3, A). In quintile II (Figure 3, B) and particularly in
quintiles III through V (Figure 3, C), however, which con-
tained progressively fewer complex conditions and sicker
patients (Table 5), repair afforded a survival advantage.
Propensity and Risk-Adjusted Comparison
After adjustment for dissimilarities in patient characteristics
between those undergoing mitral valve repair versus
replacement by propensity score, risk factors for early mor-
tality (the dominant phase of hazard, extending to about 1
year) included older age, renal dysfunction, increasing
NYHA functional class, greater left ventricular dysfunction,
and, specifically, mitral valve replacement versus mitral
valve repair (Table 6). However, the beneficial effect of
repair was reduced if the ITA was not used for coronary
revascularization, if a complex regurgitant jet pattern was
TABLE 4. Factors associated with the likelihood of mitral valve repair rather than replacement
Factor Logistic coefficient (± SD) P
Clinical status
Lower NYHA functional class* –1.51 ± 0.55 .006
Nonemergency surgery 1.71 ± 0.45 .0002
Left ventricular and mitral valve morphology
Isolated functional mitral regurgitation 1.45 ± 0.29 <.0001
Decreasing degree of regurgitation† –1.14 ± 0.30 .0001
Coronary disease
ITA grafting 0.78 ± 0.32 .02
Intercept for model, 4.78; C statistic, 0.82.
*Natural logarithmic transformation of NYHA class (ln[NYHA class]).
†Negative sign indicates decreasing likelihood of mitral valve repair and increasing likelihood of replacement.
TABLE 5. Distribution of patient and operative characteristics across propensity-matched quintiles
Quintile
Variable I (%, n = 96) II (%, n = 96) III (%, n = 97) IV (%, n = 96) V (%, n = 97)
NYHA functional class IV 67 43 29 34 9
Emergency surgery 32 5 1 0 0
Severe (grade 4) mitral regurgitation 86 71 61 30 3
Functional mitral regurgitation 19 56 78 88 93
Infarcted papillary muscle without rupture 49 38 19 11 5
Ruptured papillary muscle 32 5 3 1 2
Use of ITA graft 11 31 44 52 70
Surgeon A 25 37 37 42 29
Surgeon B 14 12 8 12 15
Mitral valve repair 42 84 93 96 97
Gillinov et al Surgery for Acquired Cardiovascular Disease
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present on echocardiography, or if bovine pericardium was
used for the annuloplasty. Figure 4 illustrates the risk-
adjusted influence of repair versus replacement in the pres-
ence and absence of a complex regurgitant jet and lateral
wall motion abnormality. A complex regurgitant jet was
common among patients with an infarcted papillary muscle
without rupture and those without severe left anterior
descending coronary artery disease (Appendix I, Table 1).
Late survival was reduced among patients in atrial fibril-
lation or with impaired renal function. Survival was better
among patients with an inferior wall motion abnormality.
We were unable to demonstrate an effect of repair versus
replacement in this hazard phase except among patients
with a lateral wall motion abnormality, whose survival was
worse with repair. Correlates of lateral segment wall motion
abnormality included absence of right coronary artery dis-
ease (Appendix I, Table 2). Thus, although survival was
generally better if there was a ruptured papillary muscle
rather than an infarcted papillary muscle or isolated func-
tional mitral regurgitation, other risk factors accounted ade-
quately for the observed overall differences (Figure 5).
Surgeons who performed fewer of these operations were
more likely to operate on an emergency basis (21% vs 6%,
P < .0001) and more likely to replace the mitral valve (30%
vs 16%) than surgeons with higher volumes. However, nei-
ther surgeon volume nor identity influenced early (P = .5) or
late (P = .9) survival.
Which Patients Benefit From Which Procedure? 
When we simulated both valve repair and valve replacement
by solving the multivariable equation twice for each patient,
the predicted difference in 7-year survival showed a repair
benefit for 66% of patients (Figure 6, A). This repair benefit
was true for both the actual repair and actual replacement
groups (Figure 6, B). The patients with the most complex
and severe conditions did not appear to benefit from mitral
valve repair; indeed, their 7-year survival was better with
replacement. However, this apparent advantage to mitral
valve replacement was partially neutralized if patients
Figure 3. Survival for matched quintiles after mitral valve repair and mitral valve replacement. Because of the small num-
ber of patients with mitral valve replacement in quintiles III through V, these quintiles are grouped together. Presentation
follows format of Figure 2. P values are for log-rank test. A, Quintile I; B, quintile II; C, quintiles III through V.
A
B C
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Figure 4. Predicted survivals after mitral valve repair and replacement for two different patients according to multi-
variable equation in Table 6. Figure shows impacts of complex regurgitant jet and lateral wall motion abnormality on
survival. A, 65-year-old patient with moderate left ventricular dysfunction, no renal dysfunction, no inferior wall
motion abnormality, requiring emergency surgery. No ITA graft was used, there was no complex regurgitant jet, and
there was no lateral wall motion abnormality. Survival would be better with valve repair than with valve replace-
ment. B, Similar patient but with complex regurgitant jet and lateral wall motion abnormality. Survival predicted to
be generally poor, with no advantage of repair.
TABLE 6. Multivariable analyses of death with all patients
Hazard phase
Early Late
Incremental risk factors Coefficient (± SD) P Coefficient (± SD) P
Demographic characteristics
Older age* 0.73 ± 0.18 <.0001 —
Clinical status
Higher NYHA functional class† 0.68 ± 0.15 <.0001 —
Cardiac comorbidity
Increasing severity of wall motion abnormality‡ 0.069 ± 0.022 .001 —
Wall motion abnormality site inferior§ — –0.85 ± 0.28 .002
Wall motion abnormality site lateral in patients with repair — 0.79 ± 0.29 .006
Preoperative atrial fibrillation — 1.05 ± 0.26 <.0001
Valve pathophysiology
Complex jet direction in repair patients 1.21 ± 0.36 .0007 —
Noncardiac comorbidity
Higher preoperative creatinine 0.26 ± 0.061 <.0001 —
Higher preoperative blood urea nitrogen¶ — 0.70 ± 0.25 .005
Operation
Mitral valve repair§ –2.12 ± 0.52 <.0001 0.11 ± 0.62 .9
Use of bovine pericardial ring in patients with repair 0.48 ± 0.27 .07 —
Absence of ITA grafting in patients with repair 1.22 ± 0.41 .003 —
Propensity score 1.08 ± 0.62 .08 0.18 ± 0.99 .9 
*Exponential transformation of age in years (exp[age/50]).
†NYHA functional classes I through V, where class V is equivalent to class IV with emergency surgery.
‡Grades are as follows: 1, normal; 2, mild; 3, moderate; 4, severe, square transformation.
§Negative coefficient indicates beneficial association.
Interaction term.
¶Natural logarithmic transformation of blood urea nitrogen in milligrams per deciliter (ln[blood urea nitrogen]).
A B
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undergoing repair received an ITA graft and an annuloplasty
by a technique other than a bovine pericardial strip (see
Appendix V).
Is Mitral Valve Repair Durable?
At the end of repair, 6 patients were found to have at least
moderate residual mitral regurgitation and were returned to
cardiopulmonary bypass for replacement of the valve. When
these cases were added as repair failures, freedoms from
mitral valve reoperation were 98% at 30 days, 96% at 1
year, and 91% at 5 years (Figure 7).
Discussion
Classification of Ischemic Mitral Regurgitation
All patients in this report had mitral regurgitation caused by
a previous myocardial infarction. From analysis of echocar-
diograms and operative reports, we were able to classify
patients into three groups according to the mechanism of
regurgitation: ruptured papillary muscle, infarcted papillary
muscle without rupture, and functional ischemic mitral
regurgitation. Others have proposed similar classification
schemes.5-11 Differences among these schemes create con-
fusion. We propose a simple system of classification that
encompasses all patients with ischemic mitral regurgitation
caused by previous myocardial infarction. This system
should permit uniform reporting of surgical results and
meaningful comparisons between different series. Further-
more, in this system, the mechanism of mitral regurgitation
dictates the repair techniques used when mitral reconstruc-
tion is attempted.
It is of particular importance, however, to verify that the
mitral regurgitation is, in fact, caused by a myocardial
infarction. Most patients with concomitant mitral regurgita-
tion and coronary artery disease do not have ischemic mitral
regurgitation. Rather, they have a primary mitral valve
pathologic condition (degenerative or rheumatic) and coex-
isting coronary artery disease.
The minority of patients with ischemic mitral regurgitation
have pathologic changes of the papillary muscle. Papillary
muscle rupture, which is usually an acute and catastrophic
event, has a different presentation from papillary muscle infarc-
tion with an elongated but intact papillary muscle. Repair tech-
niques for these two conditions differ.9,10,12 Although these
conditions represent end points of the same pathologic process,
it is thus useful to consider them as distinct entities.
Most patients with ischemic mitral regurgitation have
functional ischemic mitral regurgitation. In such cases, the
mitral leaflets and subvalvular apparatus appear structurally
normal on echocardiography and direct inspection. The
leaflets fail to coapt during ventricular systole and may
appear restricted, producing a regurgitant jet that is usually
central but occasionally eccentric (complex).5,6,13 We agree
with others that this entity should be termed functional
ischemic mitral regurgitation. The term papillary muscle
dysfunction7 should be used with caution; although papillary
muscle dysfunction may contribute to transient mitral regur-
gitation in patients with intermittent ischemia, it does not
explain the mechanism of functional mitral regurgitation.
The mechanism of functional ischemic mitral regurgita-
tion has been debated. It is probably a complex entity pro-
Figure 5. Survival according to cause of ischemic mitral regurgitation. According to univariate analysis, patients with
papillary muscle rupture appear to have superior survival. Depiction as in Figure 2.
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duced by changes in annular, ventricular, and papillary mus-
cle geometry and function.11,14,15 The mechanism may dif-
fer from patient to patient, depending on the site and extent
of myocardial infarction. Pathologic examinations by
Bulkley and Roberts16 suggest that isolated annular dilata-
tion is a rare cause of mitral regurgitation; however, others
believe that annular dilatation is an important component of
functional ischemic mitral regurgitation.6,11,17,18 The pri-
mary pathologic condition may involve alterations in ven-
tricular and papillary muscle geometry, producing a
tethering effect on the mitral leaflets.5,8,11 Although the
mechanism of functional ischemic mitral regurgitation is
unclear, the most important point is that these patients have
normal mitral leaflets and subvalvular apparatus, which
allows treatment by annuloplasty alone.5,6,8,13
The mechanism of ischemic mitral regurgitation has
been investigated in several animal models. In an acute
sheep model, Gorman found that large posterior infarction
caused asymmetric annular dilatation and changes in papil-
lary muscle geometry.19 Both posterior papillary muscle
infarction and left ventricular dilatation were necessary to
produce ischemic mitral regurgitation; left ventricular
dilatation alone did not produce mitral regurgitation.20 An
elegant study from Stanford University of acute ischemic
mitral regurgitation suggested that early systolic annular
dilatation, shape change, and altered posterior papillary
Surgery for Acquired Cardiovascular Disease Gillinov et al
Figure 6. Cumulative distribution of differences in 7-year survival between mitral valve repair and replacement.
Patients to right of 0 difference are predicted to benefit from mitral valve repair. A, Overall cumulative distribution;
B, cumulative distribution of survival differences for patients with actual repair (solid line) and actual replacement
(dashed line).
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muscle motion are the primary mechanisms of acute
ischemic mitral regurgitation.21 Experimental studies in
other models suggest roles for alterations in left ventricular
shape22 and changes in distance from the papillary muscles
to the anulus.23 These studies of acute ischemic mitral
regurgitation in animal models are limited in their ability to
explain the mechanism of human ischemic mitral regurgita-
tion. Nevertheless, they demonstrate that functional
ischemic mitral regurgitation is probably more complicated
in its pathogenesis than simple annular dilatation.
Implications of Differences Among Patients Undergoing
Mitral Valve Repair Versus Replacement
Patients who underwent a mitral valve repair differed in impor-
tant respects from many of the patients who underwent replace-
ment. We therefore approached this potential confounding of
the comparison by using the propensity score.1-3 This is one of
a suite of balancing scores whereby patients can be matched
multivariably (balanced) at the expense of imbalanced numbers
of patients from each group in each comparison (Table 5). The
imbalance in numbers renders the comparison in quintiles III
through V tenuous. This extreme imbalance revealed that we
were dealing with a wide spectrum of disease in this group of
patients and that less ill patients with fewer sequelae of this
myocardial damage whose surgery was elective preferentially
underwent repair. We believe that our use of the propensity
score as a covariable in our modeling and our extensive sub-
group and interaction analyses adjusted well for these imbal-
ances (see Appendix III and Appendix IV for details).
Mitral Valve Repair Versus Replacement
Patients with ischemic mitral regurgitation have an unfavor-
able prognosis, with poor survival relative to patients with
other causes of mitral dysfunction.6,7,24 It is therefore
important to determine which factors influence early and
late survival for risk stratification and alteration of surgical
approach that might improve survival.
We documented several risk factors for early and late
death after surgical treatment of ischemic mitral regurgita-
tion. These included such general factors as older age,
advanced NYHA functional class, severe left ventricular dys-
function, preoperative atrial fibrillation, and renal dysfunc-
tion. In addition, patients with inferior wall motion
abnormalities, corresponding to right coronary artery infarcts,
had better survival than did patients with other wall motion
abnormalities. Others have reported similar findings.6,7
Which Patients Benefit From Repair?
The previously discussed information can be used for risk
stratification, but does not afford the surgeon the opportunity
to influence outcome by surgical technique. We therefore
asked the specific question, “For whom is repair better than
replacement as treatment for ischemic mitral regurgitation?”
The answer is that repair confers a survival advantage for
most patients with ischemic mitral regurgitation. The impact
of mitral valve repair was investigated with a variety of
methods. Propensity matching was invaluable in the analy-
sis, because there was a great deal of interaction between it
and outcome. Across all propensity-matched quintiles,
mitral valve replacement resulted in a fairly uniform out-
come, with poor long-term survival independent of patient
status. In contrast, mitral valve repair produced a modulated
result across the quintiles. Thus patients who underwent
elective surgery and had a more stable condition derived a
survival benefit from mitral valve repair (see Appendix IV).
A more detailed examination of patients in the repair
group revealed that they had reduced survival if they had a lat-
Figure 7. Freedom from mitral valve replacement after mitral valve repair. Depiction as in Figure 2.
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eral infarct or a complex regurgitant jet. The reason for these
findings is not entirely clear but may relate to the extent of the
wall motion abnormality and difficulty in achieving a perfect
repair in cases of complex regurgitant jets. Patients who
underwent mitral valve repair had improved survival if they
had an ITA graft and a formal annuloplasty band or ring
(rather than a bovine pericardial strip).
Several investigators have suggested that repair is better
than replacement for patients with ischemic mitral regurgita-
tion.7,17 Others, however, have documented equivalent late
survivals after repair and replacement.5,24 Chordal preserva-
tion at mitral valve replacement may be an important means of
improving survival.5 Cohn and colleagues6 and Dion and asso-
ciates14 concluded that the pathophysiologic mechanism of
mitral regurgitation and the mode of presentation of the patient
were more important determinants of outcome than was the
surgical technique. In an earlier analysis of a smaller number
of patients, we found better survival after repair among
patients with leaflet prolapse than among those with func-
tional ischemic mitral regurgitation.10 This study suggests a
far more complicated interaction, however, with important
impacts on results of patient presentation, specific regurgitant
and wall motion abnormalities, and surgical technique.
Surgical techniques for mitral valve repair in patients
with ischemic mitral regurgitation have been described by
others.5,6,8,10,12 Papillary muscle rupture was repaired by
papillary muscle reimplantation or occasionally by resec-
tion of a prolapsing portion of the posterior leaflet. Papillary
muscle infarction was repaired by papillary muscle shorten-
ing. Functional ischemic mitral regurgitation was repaired
by annuloplasty alone. We prefer to use an undersized annu-
loplasty, and 79% of patients who underwent mitral valve
repair had an annuloplasty that was 30 mm or smaller.
Others have also reported excellent results with an under-
sized annuloplasty for functional ischemic mitral regurgita-
tion.9,13,15 Frater13 believes that the undersized annuloplasty
compensates for posterior left ventricular dilatation. Bolling
and colleagues15 suggest that an undersized annuloplasty
may in time result in reversal of ventricular remodeling. The
technique of annuloplasty is important. Bovine pericardial
annuloplasty jeopardized late survival, and others have
demonstrated that ring annuloplasty is superior to suture
annuloplasty for patients with ischemic mitral regurgita-
tion.9 Experimental data suggest that posterior annuloplasty
may be sufficient to correct functional ischemic mitral
regurgitation.21 Our own data confirm this, because sur-
vivals were similar with the Cosgrove-Edwards annulo-
plasty band and the Carpentier-Edwards annuloplasty ring.
Although some favor cardiac transplantation for certain
subsets of patients with ischemic mitral regurgitation,24 we
have not used this strategy. Contemporary 5- and 10-year
survivals after cardiac transplantation are 68% and 46%,
rendering this an imperfect option.25 In addition, most
patients in this series were elderly, making them unlikely
candidates for transplantation.
Limitations
This was a nonrandomized clinical study. By using the
propensity score, we attempted to adjust the multivariable
analyses of outcomes for nonrandom selection bias related
to choice of valvular procedure.
The need for surgical intervention for patients with mod-
erate (2+) mitral regurgitation remains a matter of debate
and should be the subject of a prospective study. The ques-
tion cannot be addressed by this clinical study.
Serial echocardiographic follow-up assessment of mitral
valve function was unavailable for most patients who under-
went mitral valve repair. Therefore the data do not allow dis-
crimination of patients who had recurrent mitral valve
dysfunction but did not undergo reoperation.
The end points investigated in this study were death and
mitral valve reoperation. We did not analyze other valve-related
complications, all of which have been thoroughly documented
in the literature for mitral valve repair and replacement.
We were unable to determine from review of all opera-
tive reports which patients with mitral valve replacement
had preservation of all or part of the subvalvular apparatus.
The impact of this surgical technique therefore could not be
analyzed. Only a single patient in this study had an Alfieri
stitch. The impact of the Alfieri stitch in ischemic mitral
regurgitation is the subject of an ongoing study.
Finally, patients with intermittent ischemic mitral regur-
gitation treated by coronary revascularization alone were
not included in this analysis.
Clinical Inferences and Decision-Making
Patients who require mitral valve surgery for ischemic
mitral regurgitation can be classified by echocardiography
and direct inspection as having a ruptured papillary muscle,
infarcted but unruptured papillary muscle, or functional
ischemic mitral regurgitation. Late survival is poor for all
groups, with most patients dying within 7 years of surgery.
However, choice of surgical procedure has an important
impact on late survival. Most patients derive a survival advan-
tage from mitral valve repair rather than replacement. Among
the most severely ill patients, the survival benefit of mitral
valve repair is diminished. When mitral valve repair is per-
formed, a formal annuloplasty should be used, and left ante-
rior descending disease should be treated by ITA grafting.
We thank Karen Mrazeck for assembling and verifying the clin-
ical data and performing the follow-up; John Hendricks, Linda
DiPaola, and Maura Schnauffer for constructing the data set; and
Lucinda Mitchin for expert secretarial assistance.
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Discussion
Dr D. Craig Miller (Stanford, Calif). I commend Wierup and
colleagues for a fine presentation of a complex data set and com-
pliment them on this massive undertaking, which took 2 years to
complete. This report is the best we can hope for in encompassing
this challenging topic and finally gets rid, for the most part, of the
problem of comparing apples and oranges, which we have faced
for many years.
This is the largest report to date on surgically treated patients
with ischemic mitral regurgitation, and it should be emphasized
that this is a “clean” series in that all of these patients had causal
ischemic mitral regurgitation as a consequence of coronary disease
and not just incidental coronary artery disease, something which
has confounded previous reports. Now that we have large numbers
of patients analyzed by the unbelievable statistical prowess of Dr
Blackstone, who has truly done statistical backflips in gleaning
meaningful messages, what have we learned?
First, patients with ischemic mitral regurgitation treated either way
have a soberingly poor 5- to 7-year prognosis. This sad fact, which
concurs with previous honest reports, begs the question of whether
transplantation might be a better option for suitable individuals.
Second, we now know that mitral annuloplasty, even if per-
formed at the heralded Cleveland Clinic Foundation, does not con-
fer immortality. Indeed, in the sickest quintile of patients there really
was no difference in survival between repair and replacement. Why?
Well, as always, it is probably patient selection first, patient selection
second, and patient selection third, which brings up the possible
presence of subtle patient referral or patient selection biases in this
report. There probably is a difference in patient substrate between
the patient with ischemic mitral regurgitation who has been on sur-
geon X’s waiting list for 2 or 3 months and has an operation done
during daylight hours and the patient who is airlifted in so that an
emergency operation can be undertaken in the middle of the night.
Dr Wierup, did you look for the influence of such possible bias by
adjusting results by surgeon, or perhaps maybe even by the time of
day or night that the operation commenced?
Is the take-home message really that the low-risk patients with
“functional” ischemic mitral regurgitation, a central jet with
Carpentier type I (or normal) leaflet motion, really do better
after repair than they would have if they had received a valve
replacement? This may well be the case, Dr Wierup, but
because you do not know who had what type of replacement or
what type of chorda-sparing replacement, how can we be sure
the survival would not have been equivalent if the patients
undergoing valve replacement had had complete or partial
chordal preservation? For example, you stated that survivals
were similar after valve replacement and repair in the sickest,
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highest-risk quintile of patients. Later, you mentioned that the
survival advantage of repair was partially neutralized if the
repair did not involve an ITA graft, or a Carpentier-Edwards ring
or a Cosgrove annuloplasty band instead of vein grafting alone
or nonring pericardial strip annuloplasty. Conversely, could the
putative survival advantage of repair for the least sick, lowest-
risk patients have been potentially neutralized if all or some of
the chordae had been preserved in all the replacements?
Something predictable and reproducible is what we all want here,
especially in the middle of the night in less than ideal circumstances,
and maybe mitral valve replacement with total chordal preservation
is the way to go in many cases. Given the dismal long-term survival
of these patients, this patient substrate is an ideal indication for a tis-
sue bioprosthesis, no matter the patient’s age.
Third, if repair really is that much better than replacement, why
wasn’t this evident for the sickest patients? Indeed, I was even
struck by the modest magnitude of survival advantage in the least
sick quintiles. None of us can make a silk purse out of a sow’s ear
here, and I think that is the crux of the matter; but this sad news
could be due to the challenging subset of cases with a “complex”
mitral regurgitation jet. I think that this subgroup probably had the
restricted systolic leaflet motion, or so-called Carpentier type III
leaflet motion, and apical tethering of the leaflets. It is a much more
complicated setting than simple annular dilatation and a central
mitral regurgitation jet, where a small ring probably is adequate.
Are you and your colleagues at the Clinic in such circumstances
now adding other adjuncts to your repair techniques, such as a com-
missuroplasty or an Alfieri stitch? If so, where? In the posterome-
dial scallop or in the middle of the valve? What about actual leaflet
elongation or extension procedures such as those performed by
Kohl in Lund, Sweden, and in Toronto by Tirone David?
To sum up, none of us has all the answers yet, but this article
sure helps.
Dr Wierup. Thank you, Dr Miller. Certainly these patients face
a poor survival, and transplantation, as previously suggested by
Houseman from Berlin, is an alternative.
We have not looked for the influence of different surgeons on
the outcome, nor have we taken into account the time of day.
We are aware of the beneficial results shown by Dr David and
colleagues for preservation of the subvalvular apparatus in mitral
valve replacement, and our current practice is to preserve as much
as possible of the subvalvular apparatus when we replace the valve.
This information was not stated in some of the charts, however,
and we elected not to analyze this aspect.
Regarding mitral valve replacement in the sickest patients,
analyses showed slightly different survival patterns for replace-
ment versus repair, with more early deaths and fewer later ones,
resulting in no overall survival advantage.
Let me comment on the “complex jet.” In our material 15% of
the patients had a complex jet, which was frequently seen at the
posteromedial commissure. Our current techniques are undersizing
of the annuloplasty and commissuroplasty at the posteromedial
commissure. We have not yet started with leaflet extension, but it
could certainly be an alternative.
Dr Robert A. Dion (Leiden, The Netherlands). What is your
rationale for adding a mitral valve procedure for patients with only
moderate or fluctuating or intermittent mitral regurgitation?
Dr Wierup. We make sure that the patient has adequate preload
and afterload, and if the regurgitation does increase to more than
2+, we do not operate on the valve.
Dr Alain Carpentier (Paris, France). First of all, I congratu-
late you on this excellent presentation and pointing out the superi-
ority of valve repair. Let me talk about just the patients with not as
good a result in the group of very sick patients.
It was mentioned that a solution to that problem could be leaflet
extension. I do not recommend leaflet extension for this particular
group because it is just time-consuming, and for this particular sub-
group of patients it will not be the solution. I would rather recommend
downsizing the ring. Have you tried to downsize the annuloplasty in
this particular group, which I think is a simple solution?
Dr Wierup. Yes, our current practice is to undersize in this entity.
Appendix I
Wall Motion Abnormalities
The sources of left ventricular wall motion data were, in order of
preference, the intraoperative echocardiogram, preoperative
transthoracic echocardiogram, and preoperative left ventriculo-
gram. Five general ventricular segments were recorded (Figure 1).
The anterior segment included anterior, anteroseptal, anterolateral,
and anteroapical locations. The septal segment included septal,
anteroseptal, and inferoseptal locations. The inferior segment
included inferior, inferior-posterior, and inferior-septal locations.
The lateral segment included lateral, posterolateral, and anterolat-
eral locations. The posterior segment included posterior, postero-
lateral, and inferior-posterior locations. Thus when composite
locations were encountered (eg, anteroseptal), abnormalities were
recorded in both anterior and septal segments.
Each location was assessed as normal or abnormal. An abnor-
mal assessment was recorded for findings of hypokinesis, akinesis,
dyskinesis, or aneurysm.
Surgery for Acquired Cardiovascular Disease Gillinov et al
Appendix I, TABLE 2. Correlates of lateral segment wall
motion abnormality
Factor Logistic coefficient (± SD) P
Younger age* –0.31 ± 0.156 .05
Absence of right coronary –1.32 ± 0.45 .004
artery disease
Increasing left ventricular 0.12 ± 0.022 <.0001
dysfunction†
Intercept for model, 1.04; C statistic, 0.69.
*Exponential transformation of age in years (exp[age/50]).
†Squared transformation of dysfunction ([dysfunction]2).
Appendix I, TABLE 1. Correlates of complex regurgitant jet
Factor Logistic coefficient (± SD) P
Infarcted papillary muscle 0.95 ± 0.30 .002
without rupture
Absence of left anterior descending –0.61 ± 0.31 .05
coronary artery stenosis ≥70%
Intercept for model, –1.71; C statistic, 0.67.
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Appendix II
Details of Data Analysis
Propensity analysis. The propensity analysis (see Methods)
resulted in a logistic equation from which the probability of receiv-
ing mitral valve repair rather than replacement could be calculated
for each patient. The propensity score was constructed with regard
to patient outcome, and the calculation was made regardless of
whether the patient actually underwent repair or replacement.
Each patient’s propensity score was calculated from the sum of
the values for all variables in the model multiplied by their respec-
tive logistic coefficients. The patients were then sorted according
to the propensity score. Patients with similar propensity scores
were well matched for all these factors. Only in the first quintile,
however, was there a large, well-matched comparison group of
patients. Characteristics of this quintile differed in many important
ways from those of the others, particularly with respect to the com-
plexity and consequences of the disease and the prevalence of
replacement versus mitral valve repair (Table 5).
Risk factor identification. In the analysis of risk factors, it
became clear that the propensity score itself represented a gradient
of mortality risk, and within quintiles an increasingly different out-
come for repair and replacement. We therefore developed models for
the repair and replacement groups separately (Appendix II, Table 1;
Appendix II, Table 2). We then combined these analyses, examining
every interaction with repair versus replacement. This yielded a
model that better fit the data than did the two separate analyses.
Variable selection used two complementary techniques: guided
entry of variables into each hazard phase26 and bootstrap resam-
pling variable selection (so-called “bagging”).27,28 For the latter,
the data set was randomly sampled with replacement to generate a
data set of the same size. This was repeated 500 times. Each data
set was analyzed by automated forward stepwise variable selec-
tion. The variables entered into the final model by the directed
approach relied on the frequency with which variables appeared in
these 500 models. Generally, factors that appeared in 50% or more
of the models were retained. The P value criterion for retention of
variables in the final models with this combined variable selection
approach was .1, except for the variables repair versus replace-
ment and propensity score, which were forced into the models.
Management of missing data. The data exhibited typical sporadic
missing value difficulties. Nearly every patient had missing values for
at least one variable. In this setting it is better to retain all patients than
to delete individuals with missing values. Therefore all variables were
Appendix II, TABLE 1. Multivariable analyses of death
within replacement group (n = 85)
Early hazard phase
Incremental risk factors Coefficient (± SD) P
Demographic characteristics
Older age* 0.79 ± 0.35 .02
Cardiac comorbidity
Increasing severity of wall 0.09 ± 0.038 .02
motion abnormality†
Noncardiac comorbidity
Renal disease 1.07 ± 0.39 .02
*Exponential transformation of age in years (exp[age/50]).
‡Grades are as follows: 1, normal; 2, mild; 3, moderate; 4, severe, square
transformation.
Appendix II, TABLE 2. Multivariable analyses of death within repair group (n = 397)
Hazard phase
Early Late
Incremental risk factors Coefficient (± SD) P Coefficient (± SD) P
Demographic characteristics
Older age* 0.61 ± 0.21 .0004 —
Clinical status
Higher NYHA functional class† 0.63 ± 0.16 <.0001 —
Cardiac comorbidity
Wall motion abnormality site inferior‡ — –0.83 ± 0.29 .004
Wall motion abnormality site lateral — 0.84 ± 0.29 .004
Preoperative atrial fibrillation — 1.07 ± 0.26 <.0001
Valve pathophysiology
Complex jet direction 1.10 ± 0.36 .002 —
Noncardiac comorbidity
Higher preoperative creatinine 0.24 ± 0.071 .0005 —
Higher preoperative blood urea nitrogen§ — 0.71 ± 0.26 .007
Operation
Use of bovine pericardial ring 0.51 ± 0.27 .05 —
Absence of ITA grafting 1.03 ± 0.38 .007 —
*Exponential transformation (exp[age/50]).
†NYHA functional classes I through V, where V is equivalent to IV with emergency surgery.
‡Negative coefficient indicates a beneficial association.
§Natural logarithmic transformation (ln[blood urea nitrogen]).
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scrutinized with respect to the pattern of missing values. If more than
20% to 25% of values were missing, the variable was not considered
in any analyses. In the remaining cases, the missing informative impu-
tation was not possible. We therefore assumed that the values were
missing at random and substituted the mean value for the remainder
of the group for the missing values. In addition, we generated indica-
tor variables for each variable with missing values; the value was 0 if
the value was present and 1 if it was missing. We incorporated these
indicator variables in the propensity score to distribute them appropri-
ately, and we tested for their significance in multivariable modeling. In
all cases, patients with missing values behaved with respect to out-
come the same (P > .1) as those with values.
Analysis of benefit. In addition to comparing 7-year survivals,
we not only simulated the 7-year survival difference between
repair and replacement but also constructed complete survival
curves for the patients who were predicted to fare better at 7 years
with the surgical procedure other than that which they had under-
gone. For this, the other characteristics of each were entered into
the multivariable equation (Table 6) to generate a patient-specific
survival curve and to calculate the cumulative hazard at the actual
time of follow-up. The curves were averaged and compared with
Kaplan-Meier estimates of actual outcome.29 With the sum of the
cumulative hazard values, the predicted number of deaths was
compared with the actual number.
Appendix III
Variables Considered in Risk Analyses
Demographic characteristics
• Age (years)
• Height (centimeters)
• Weight (kilograms)
• Body mass index (kilograms per square meter)
• Body surface area (square meters)
• Gender
Symptoms and clinical status
• Emergency surgery
• NYHA functional class (I through IV, and also augmented
from class IV to new class V for emergency operations)
• Preoperative use of intra-aortic balloon pump
Left ventricular function
• Preoperative acute versus remote myocardial infarction
(acute myocardial infarction occurring within 14 days of
surgery)
• Timing of most recent myocardial infarction in relation
to surgery (continuous variable)
• Severity of left ventricular dysfunction (1, none; 2, mild;
3, moderate; 4, severe)
• Site of infarction or wall motion abnormality (septal,
inferior, anterior, lateral, posterior)
• Jet direction (central, anterior, posterior, complex)
Pathophysiology of valve disease
• Degree of mitral regurgitation (1, mild; 2, moderate; 3,
moderate to severe; 4, severe)
• Mitral stenosis
• Left ventricular thromboembolism
• Mitral valve pathology: functional mitral regurgitation,
elongated or infarcted papillary muscle, rupture of papil-
lary muscle
Cardiac comorbidity
• Family history of coronary artery disease
• Preoperative atrial fibrillation
• Left ventricular dysfunction (0, normal; 1, mild; 2, mod-
erate; 3, severe)
• Coronary artery disease (maximum stenosis in left main
trunk, left anterior descending, circumflex, and right
coronary trunk systems)
• Extent of coronary system disease (1, one-system dis-
ease; 2, two-system disease; 3, three-system disease)
Noncardiac comorbidity
• Blood urea nitrogen (milligrams per deciliter)
• Creatinine (milligrams per deciliter)
• Renal disease
• Cholesterol
• Bilirubin
• Treated diabetes
• Smoking
• Hypertension
• Chronic obstructive pulmonary disease
• Peripheral vascular disease
Operation
• Mitral valve replacement versus repair
• Mitral valve repair: annuloplasty (with or without ring,
Carpentier-Edwards, Cosgrove, bovine pericardial annu-
loplasty), annular plication, annular decalcification,
leaflet resection (quadrangular or not) or suture, chordal
resection, chordal shortening or transfer, papillary mus-
cle shortening
• Surgeon (separate indicator variable for each of the 6
high-volume surgeons and an indicator for low-volume
surgeon, see Methods)
• Date of operation (number of years since January 1, 1985)
Concomitant procedures
• Coronary artery bypass grafting
• ITA grafting
• Single versus bilateral ITA grafting
• Tricuspid valve replacement or repair
Appendix IV
Repair Versus Replacement: Lines of Evidence
The answer to the question, “Is repair better than replacement?” is
not a simple yes or no but “depends.” The lines of evidence are as
follows.
1. Even though mitral valve replacement was rare for much of the
spectrum of the disease and patient condition, the survival
increased progressively after repair as patient condition became
better and the lesion became simpler, whereas survival after
replacement remained about the same (Figure 3).
2. The risk factors for the replacement group were nonspecific
(Appendix II, Table 2) compared with those for the repair group
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(Appendix II, Table 1), which allowed larger gradients of risk
to be identified for the group. A limitation of this line of evi-
dence is the relatively small number of valve replacements.
3. An initial and identical-factor multivariable analysis was gen-
erated for quintiles I and II and then extended to include
sequentially quintiles III, IV, and V (not shown). The P value
for replacement as a risk factor in the early hazard phase
steadily decreased from .3 (quintiles I and II) to .1, .08, and .02.
Appendix V
Who Benefits?
The multiple linear regression for the difference in 7-year survival
is presented in Appendix V, Table 1. When the equation is solved
for a given patient’s characteristics, a positive value predicts a ben-
efit for replacement and a negative value predicts a benefit for
repair strictly on the basis of point estimates.
Patients undergoing mitral valve replacement who were pre-
dicted to fare better with repair are shown in Appendix V, Figure 1
(see Appendix II for details of constructing these patient-specific
survival curves). Their time-related pattern of survival was better
than that observed, and the number of predicted deaths (n = 18)
was lower than the actual number (n = 27, P = .01). In contrast,
those patients who actually underwent repair but were predicted to
fare better at 7 years with replacement merely demonstrated a dif-
ferent survival pattern, with more early deaths and fewer late ones
(Appendix V, Figure 2), resulting in no saving of lives (n = 61.5
predicted vs n = 64 observed, P = .98).
Appendix V, TABLE 1. Factors influencing magnitude of
survival benefit associated with mitral valve repair versus
replacement (multiple linear regression)*
Variable Coefficient (± SD) P
Demographic characteristics
Age 0.51 ± 0.040 <.0001
Clinical status
Emergency surgery 7.2 ± 1.44 <.0001
Cardiac comorbidity
Left ventricular dysfunction† 0.78 ± 0.078 <.0001
Lateral wall motion abnormality –17.2 ± 0.82 <.0001
Inferior wall motion abnormality 6.3 ± 0.89 <.0001
Atrial fibrillation –10.7 ± 0.80 <.0001
Valve pathophysiology
Complex regurgitant jet –13.1 ± 1.09 <.0001
Noncardiac comorbidity
Blood urea nitrogen‡ –3.2 ± 1.17 <.0001
Operative variables
ITA graft 7.9 ± 0.78 <.0001
Intercept for model, –17.8; r 2, 0.68.
*A positive value for the solution of the linear regression equation is
indicative of a repair benefit, whereas a negative value is indicative of a
replacement benefit.
†Square transformation of dysfunction ([dysfunction]2).
‡Natural logarithmic transformation of blood urea nitrogen in milligrams
per deciliter (ln[blood urea nitrogen]).
Appendix V, Figure 1. Simulated mitral valve repair (solid line) for
patients actually undergoing replacement (squares depict Kaplan-
Meier estimates and confidence limits, as in Figure 2). Simulated
curve was obtained from patient-specific estimates, as described
in Appendices II and V.
Appendix V, Figure 2. Simulated mitral valve replacement (solid
line) for patients actually undergoing repair (circles depict
Kaplan-Meier estimates and confidence limits, as in Figure 2).
Simulated curve was obtained from patient-specific estimates, as
described in Appendices II and V.
